This scoping review followed the a priori guide outlined by the PRISMA (Preferred Reporting Items for Scoping Reviews and Meta-Analyses) statement. We gathered articles from PsycINFO, PubMed, Sage Journals Online, ScienceDirect, and SpringerLink.
The final analysis includes forty-four articles. Results indicate inconsistent implementation of universal screens and suggest screens assessing cannabis-specific consequences and utilizing normative data may increase patient engagement. Broadly, SBIRT for cannabis demonstrates high acceptability. However, the impact of SBIRT on behavior change across various modifications to intervention content and modality has been inconsistent. In adults, patients with primary cannabis use are not engaging in recommended treatment at similar rates to other substances. Results also suggest a lack of research addressing referral to treatment in adolescents and emerging adults.
Based on this review, we offer several to improve each component of SBRIT that may increase implementation of screens, effectiveness of brief interventions, and engagement in follow-up treatment.
方法:本范围审查遵循PRISMA(范围审查和荟萃分析的首选报告项目)声明概述的先验指南。我们收集了来自PsycINFO的文章,PubMed,Sage在线期刊,ScienceDirect,和SpringerLink。
结果:最终分析包括44篇文章。结果表明,通用屏幕的实施不一致,并建议评估大麻特异性后果和利用规范数据的屏幕可能会增加患者的参与度。广义上,用于大麻的SBIRT显示出较高的可接受性。然而,在对干预内容和方式的各种修改中,SBIRT对行为改变的影响不一致。在成年人中,主要使用大麻的患者没有以与其他物质相似的比率进行推荐的治疗。结果还表明,缺乏针对青少年和新兴成年人转诊治疗的研究。
结论:基于这篇综述,我们提供了几种改进SBRIT的每个组件,这些组件可能会增加屏幕的实现,简短干预的有效性,并参与后续治疗。